These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 33420074)

  • 1. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma.
    Behary J; Amorim N; Jiang XT; Raposo A; Gong L; McGovern E; Ibrahim R; Chu F; Stephens C; Jebeili H; Fragomeli V; Koay YC; Jackson M; O'Sullivan J; Weltman M; McCaughan G; El-Omar E; Zekry A
    Nat Commun; 2021 Jan; 12(1):187. PubMed ID: 33420074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
    Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
    Front Immunol; 2020; 11():609900. PubMed ID: 33574818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
    Ponziani FR; Bhoori S; Castelli C; Putignani L; Rivoltini L; Del Chierico F; Sanguinetti M; Morelli D; Paroni Sterbini F; Petito V; Reddel S; Calvani R; Camisaschi C; Picca A; Tuccitto A; Gasbarrini A; Pompili M; Mazzaferro V
    Hepatology; 2019 Jan; 69(1):107-120. PubMed ID: 29665135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
    Sydor S; Best J; Messerschmidt I; Manka P; Vilchez-Vargas R; Brodesser S; Lucas C; Wegehaupt A; Wenning C; Aßmuth S; Hohenester S; Link A; Faber KN; Moshage H; Cubero FJ; Friedman SL; Gerken G; Trauner M; Canbay A; Bechmann LP
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00131. PubMed ID: 32352707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
    Ezzaidi N; Zhang X; Coker OO; Yu J
    Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.
    Yan F; Zhang Q; Shi K; Zhang Y; Zhu B; Bi Y; Wang X
    Front Cell Infect Microbiol; 2023; 13():1152987. PubMed ID: 37201112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.
    Behary J; Raposo AE; Amorim NML; Zheng H; Gong L; McGovern E; Chen J; Liu K; Beretov J; Theocharous C; Jackson MT; Seet-Lee J; McCaughan GW; El-Omar EM; Zekry A
    BMC Microbiol; 2021 Apr; 21(1):113. PubMed ID: 33858327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
    Safari Z; Gérard P
    Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.
    Ma C; Kesarwala AH; Eggert T; Medina-Echeverz J; Kleiner DE; Jin P; Stroncek DF; Terabe M; Kapoor V; ElGindi M; Han M; Thornton AM; Zhang H; Egger M; Luo J; Felsher DW; McVicar DW; Weber A; Heikenwalder M; Greten TF
    Nature; 2016 Mar; 531(7593):253-7. PubMed ID: 26934227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
    Chen YH; Wu WK; Wu MS
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
    Nagashimada M; Honda M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response.
    Zhang N; Gou Y; Liang S; Chen N; Liu Y; He Q; Zhang J
    J Immunol Res; 2021; 2021():4973589. PubMed ID: 34722779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
    Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
    Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diet and gut microbiome in fatty liver and its associated liver cancer.
    Pan Y; Zhang X
    J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease.
    Yu JS; Youn GS; Choi J; Kim CH; Kim BY; Yang SJ; Lee JH; Park TS; Kim BK; Kim YB; Roh SW; Min BH; Park HJ; Yoon SJ; Lee NY; Choi YR; Kim HS; Gupta H; Sung H; Han SH; Suk KT; Lee DY
    Clin Transl Med; 2021 Dec; 11(12):e634. PubMed ID: 34965016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.